BioPOA Co., Ltd. (referred to as “BioPOA”) announced on the 12th that it has won the Grand Prize in the Green Bio sector, receiving the Minister of Agriculture, in the evaluation for Agricultural & Food R&D Technology Commercialization.
The Agricultural & Food R&D Technology Commercialization Excellence Awards are organized by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET). The awards recognize companies that have successfully overcome challenges in commercializing R&D technologies and achieved outstanding results. Finalists were selected through document screening and expert evaluations, after which the top-performing companies were ultimately chosen through a public vote.
BioPOA’s “PoaVac PRRS Live Vaccine” is a next-generation vaccine that applies the world’s first reverse genetics–based SAVE (Synthetic Attenuated Virus Engineering) technology, ensuring a high level of safety and an immune response. The vaccine is commercially available not only in the domestic market but also in overseas markets, contributing to improved productivity and effective disease prevention for swine farms.
The PoaVac PRRS Live Vaccine employs a Codon Pair Deoptimization (CPD) technique to control viral pathogenicity without altering amino acid sequences, effectively eliminating the risk of virulence reversion. As a result, the vaccine suppresses excessive viral replication that could cause adverse effects before the onset of protective immunity, thereby allowing sufficient time for the immune system to respond effectively.
Cho Sun-hee, CEO of BioPOA, stated, “The PoaVac PRRS Live Vaccine controls pathogenicity through the use of CPD and is developed by combining two domestically isolated strains, enabling it to provide broad cross-protective immunity. In addition, the vaccine shows minimal viral shedding after administration, thereby preventing circulation and reinfection within swine farms.”
He added, “Through technology transfer to CEVA, a global animal health pharmaceutical company, we have successfully entered the global market. We are currently exporting to Thailand and Cambodia, and plan to further expand into Vietnam, Mexico, and other markets.”
Cho Sun-hee further emphasized, “Beyond simply developing products, securing proprietary innovative technologies is paramount. By integrating artificial intelligence (AI) with BioPOA’s SAVE platform and reverse genetics technologies, we aim to complete a next-generation vaccine platform and establish it as a global standard in the vaccine market.”
BioPOA Co., Ltd. (referred to as “BioPOA”) announced on the 12th that it has won the Grand Prize in the Green Bio sector, receiving the Minister of Agriculture, in the evaluation for Agricultural & Food R&D Technology Commercialization.
The Agricultural & Food R&D Technology Commercialization Excellence Awards are organized by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET). The awards recognize companies that have successfully overcome challenges in commercializing R&D technologies and achieved outstanding results. Finalists were selected through document screening and expert evaluations, after which the top-performing companies were ultimately chosen through a public vote.
BioPOA’s “PoaVac PRRS Live Vaccine” is a next-generation vaccine that applies the world’s first reverse genetics–based SAVE (Synthetic Attenuated Virus Engineering) technology, ensuring a high level of safety and an immune response. The vaccine is commercially available not only in the domestic market but also in overseas markets, contributing to improved productivity and effective disease prevention for swine farms.
The PoaVac PRRS Live Vaccine employs a Codon Pair Deoptimization (CPD) technique to control viral pathogenicity without altering amino acid sequences, effectively eliminating the risk of virulence reversion. As a result, the vaccine suppresses excessive viral replication that could cause adverse effects before the onset of protective immunity, thereby allowing sufficient time for the immune system to respond effectively.
Cho Sun-hee, CEO of BioPOA, stated, “The PoaVac PRRS Live Vaccine controls pathogenicity through the use of CPD and is developed by combining two domestically isolated strains, enabling it to provide broad cross-protective immunity. In addition, the vaccine shows minimal viral shedding after administration, thereby preventing circulation and reinfection within swine farms.”
He added, “Through technology transfer to CEVA, a global animal health pharmaceutical company, we have successfully entered the global market. We are currently exporting to Thailand and Cambodia, and plan to further expand into Vietnam, Mexico, and other markets.”
Cho Sun-hee further emphasized, “Beyond simply developing products, securing proprietary innovative technologies is paramount. By integrating artificial intelligence (AI) with BioPOA’s SAVE platform and reverse genetics technologies, we aim to complete a next-generation vaccine platform and establish it as a global standard in the vaccine market.”